Boehringer Ingelheim

Found 2254 clinical trials|View Analysis

Sort by:

Need a comprehensive medical report on "Boehringer Ingelheim"?

Analyze the latest clinical research and treatment options

Summarize scientific findings from medical journals

Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lefradafiban tablet
Drug: Pantoprazole tablet
Device: Lefradafiban double chamber sachet

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02264119

Bioequivalence of Telmisartan Film-coated Tablet Compared With the Conventional Telmisartan Tablet Following Oral Administration in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan conventional tablet
Drug: Telmisartan film coated tablet

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02263989

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BEA 2180 BR
Drug: Spiriva
Device: Respimat® A 4
Drug: Methacholine Chloride

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 101

Registration Number: NCT02263976

Effects on the Airway Lumen of Talsaclidine in Combination With Propranolol in Comparison to the Effects of the Monosubstances in Healthy Elderly Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Talsaclidine
Drug: Propranolol

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02264093

Investigation of Pharmacokinetics of BIBX 245 CL and Safety in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBX 245 CL- fasted
Drug: BIBX 245 CL - fed

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT02264197

Safety, Tolerability, Biological Effects and Pharmacokinetics of BIIL 284 BS in Healthy Males

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BIIL 284 oral solution
Drug: BIIL 284 wetability improved formulation (WIF) tablets

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 95

Registration Number: NCT02265302

Pharmacokinetics of Talsaclidine After Administration to Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]talsaclidine, iv
Drug: [14C]talsaclidine, oral

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 6

Registration Number: NCT02264054

Pharmacokinetics and Safety of WAL2014 (Talsaclidine) in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Talsaclidine
Drug: Placebo

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02264067

Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, to Healthy Male and Female Volunteers, With an Intra-individual Comparison to Moxifloxacin in a Subset of Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cilobradine, high, film-coated tablets
Drug: Moxifloxacin, film-coated tablets
Drug: Cilobradine, low, film-coated tablets
Drug: Placebo, film-coated tablets

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 125

Registration Number: NCT02264015

Pharmacokinetics and Safety of WAL2014 (Talsaclidine) Administered Orally to Healthy Adult Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: WAL2014
Drug: Placebo

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02264080

AI-Powered Research

Premium Access

Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban in Healthy Subjects

Bioequivalence of Telmisartan Film-coated Tablet Compared With the Conventional Telmisartan Tablet Following Oral Administration in Healthy Male Volunteers

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects

Effects on the Airway Lumen of Talsaclidine in Combination With Propranolol in Comparison to the Effects of the Monosubstances in Healthy Elderly Male Volunteers

Investigation of Pharmacokinetics of BIBX 245 CL and Safety in Healthy Subjects

Safety, Tolerability, Biological Effects and Pharmacokinetics of BIIL 284 BS in Healthy Males

Pharmacokinetics of Talsaclidine After Administration to Healthy Subjects

Pharmacokinetics and Safety of WAL2014 (Talsaclidine) in Healthy Male Volunteers

Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, to Healthy Male and Female Volunteers, With an Intra-individual Comparison to Moxifloxacin in a Subset of Volunteers

Pharmacokinetics and Safety of WAL2014 (Talsaclidine) Administered Orally to Healthy Adult Male Volunteers